Table 1 Calculations to determine the likelihood that an HIV+ CD4 T cell contributed to assay outcome

From: Monocyte-derived macrophages contain persistent latent HIV reservoirs

Participant

IUPM MDM

IUPM CD4

No. CD3+ T cells in largest MDM-QVOA well

% CD3+/CD4+ cells in blood

No. CD4+ T cells in largest MDM-QVOA well

% chance of an HIV+ CD4 T cell in largest MDM-QVOA well

CP11-1

0.44

1.59

0.4b

53.9

0.2

0.00004

CP11-2

0.16

1.59a

0.7b

52.3

0.4

0.00006

CP11-3

0.41

1.59a

13.1

54.6

7.1

0.00114

CP21-1

0.34

0.55

1.1

55.9

0.6

0.00004

CP21-2

0.28

0.55a

0.5b

56

0.3

0.00002

CP21-3

0.08

0.55a

61.9

60

37.1

0.00206

CP25

0.24

8.08

0.8b

42

0.4

0.00029

CP36-1

15.8

9.50

5.2

31.5

1.7

0.00157

CP36-2

0.6

2.40

1.7

42

0.7

0.00017

CP39

<LOD

<LOD

0.4b

39.4

0.1

NA

CP56-1

<LOD

0.70

902.6

42.6

384.5

0.02691

CP56-2

<LOD

0.70a

7.8

43.3

3.4

0.00024

CP67

2.84

1.12

0.1b

38.4

0.0

0.00000

CP71

<LOD

0.52

3.3

40.2

1.3

0.00007

CP75

<LOD

1.78

0.2b

74.4

0.1

0.00002

CP77

<LOD

13.84

10.6

61.2

6.5

0.00902

  1. aCD4 IUPM used from first visit for calculation.
  2. bLOD was used for TCRβ calculation if results were below limit of detection.